You are here » Home » Companies » Company Overview » Ajanta Pharma Ltd

Ajanta Pharma Ltd.

BSE: 532331 Sector: Health care
NSE: AJANTPHARM ISIN Code: INE031B01049
BSE LIVE 15:40 | 09 Dec 1871.95 -33.30
(-1.75%)
OPEN

1917.00

HIGH

1920.35

LOW

1868.00

NSE LIVE 15:58 | 09 Dec 1872.50 -33.40
(-1.75%)
OPEN

1915.00

HIGH

1925.00

LOW

1870.00

OPEN 1917.00
PREVIOUS CLOSE 1905.25
VOLUME 4897
52-Week high 2150.00
52-Week low 1103.00
P/E 35.13
Mkt Cap.(Rs cr) 16473.16
Buy Price 0.00
Buy Qty 0.00
Sell Price 0.00
Sell Qty 0.00
OPEN 1917.00
CLOSE 1905.25
VOLUME 4897
52-Week high 2150.00
52-Week low 1103.00
P/E 35.13
Mkt Cap.(Rs cr) 16473.16
Buy Price 0.00
Buy Qty 0.00
Sell Price 0.00
Sell Qty 0.00

Ajanta Pharma Ltd. (AJANTPHARM) - Chairman Speech

Company chairman speech

WE HAVE OVER 1400 PRODUCTS REGISTERED AND OVER 1600 PRODUCTS WAITING FOR APPROVAL INVARIOUS COUNTRIES.

DEAR SHAREHOLDERS

Our strategy of ‘The Right Things at the Right Time’ focuses on identifyingopportunities and capitalising on them ahead of others. We have been consistentlyfollowing this approach and have been largely successful in our endeavour. With thisstrategy we have been able to be among the leaders in the markets where we are present.All our businesses continue to perform in-line with our expectations. We remain committedand focused on existing geographies and therapeutic segments to drive above industrygrowth consistently. We continue to take proactive steps and make right investments ininfrastructure - manufacturing and R&D - at the right time.

Last decade has been particularly significant for us as we grew at 23% CAGR on theback of our branded generic business in India and Emerging markets registering a strongperformance and building a sustainable scalable and profitable business model.

Understanding the market applying science with commitment and the passion to deliverthe best cures are inherently present in our DNA. We have over 1400 products registeredcurrently and over 1600 products are waiting for approval in various countries.

We have built various manufacturing facilities meeting the global standards andcontinue to raise the bar in meeting regulatory compliances.

We have acquired the competence in the formulation development space and continue toclimb the value chain in developing complex products.

WE CONTINUE TO TAKE PROACTIVE STEPS AND MAKE RIGHT INVESTMENTS IN INFRASTRUCTURE -MANUFACTURING AND R&D - AT THE RIGHT TIME

We will consistently focus on building the right capabilities and competencies to caterto the emerging and unmet needs across the globe. Ajanta will continue to harnesspotential across global markets and generate sustainable value for all stakeholders.

Sincerely

YOGESH AGRAWAL

Managing Director

LETTER FROM JOINT MANAGING DIRECTOR

AT AJANTA WE HAVE EMBEDDED INNOVATION IN THE BUSINESS MODEL PRODUCTS AND THE SUPPLYCHAIN.

DEAR SHAREHOLDERS

As the pharmaceutical industry is constantly evolving it means we also have totransform at every step. How do we do that? The answer is through relentless innovation.At Ajanta we have embedded innovation in the business model products and the supplychain because that is critical for the industry going forward. It is more and morerelevant to discover unmet needs and develop new drugs.

Our aim is to use new science and competencies to meet the aspirations of customersglobally. We identify potential needs develop breakthrough products in India using theright processes and marketing them right to patients. Our newly launched productsvindicate our Company’s mission to improving outcomes for individual patients. Werealised our goals through perfecting our business processes.

We expect a healthy future because of a strong R&D pipeline. Our new products likeWrinclar an anti-wrinkle cream that works at molecular level to wipe off wrinkles andKetriplin C-efficiently treats

Diabetic Peripheral Neuropathy are breakthrough innovations that we brought into Indiain 2014 -15. We are exploring growth opportunities in pain management and aim to make manymore breakthroughs in the years ahead.

We believe that the quality of our sales force interactions and the product’sability to address important medical needs have resulted in our success.

We are committed to accelerate our R&D efforts and the overall execution of ourshort term and long term strategies. We will also continue to reinforce our values ofexcellence integrity and empathy.

WE IDENTIFY POTENTIAL NEEDS DEVELOP BREAK THROUGH PRODUCTS USING THE RIGHT PROCESSESAND OFFERING THEM RIGHT TO PATIENTS.

Our aim is to live up to our high standards sustain industry-leading performance andfind solutions that exceed expectations. We seek the support and trust of all ourstakeholders in this endeavour.

Sincerely

RAJESH AGRAWAL

Joint Managing Director

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard